Is It Time to Cash In on Meridian Bioscience?
Meridian Bioscience (NASDAQ: VIVO) ran past its 52-week high last week, closing on Monday at $19.69. The diagnostic testing company, which has thrived during the COVID-19 pandemic, had record revenue in the first quarter. The question is, is it time to get out and take profits yet?
The short answer: probably not. For one thing, the pandemic appears likely to drag on for some time, and while many companies are working on a vaccine, there's no guarantee that one will be produced (or when). Until a successful vaccine comes along, the need for virus testing will grow, especially as workers begin to return to the office. Plus, there are other viruses on the horizon that Meridian's diagnostic tools will be able to help with.
Source Fool.com